Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Guardian Pharmacy Services, Inc.NYSE: GRDN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $5.81M rose 5.8% year over year, behind the +11.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Depreciation & amortization amounted to 1.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +11.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 22.34M USD
- Year-over-year change
- +13.0%
- 4-year CAGR
- +7.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.34M | +13.0% |
| FY2024 | 2024-12-31 | 19.77M | +8.4% |
| FY2023 | 2023-12-31 | 18.23M | +10.1% |
| FY2022 | 2022-12-31 | 16.56M | +0.2% |
| FY2021 | 2021-12-31 | 16.53M | — |
Depreciation & Amortization vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 depreciation & amortization of $23.36M is the 6th largest of the 11 companies compared; the peer median is $15.21M.
- Its year-over-year change of +11.8% is the 3rd highest of 11, against a peer median of +2.2%.
- Depreciation & amortization amounts to 1.6% of revenue for GRDN, versus a peer median of 3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $447.8M | +0.5% | +15.9% | 16.9% | |
| LTM Sep 2026 | $49.13M | +10.2% | +3.5% | 3.1% | |
| LTM Jun 2026 | $45.93M | +12.6% | +9.9% | 7.4% | |
| LTM Sep 2026 | $26.48M | +6.6% | -3.3% | 5.8% | |
| LTM Sep 2026 | $23.78M | +3.1% | -15.1% | 1.2% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $23.36M | +11.8% | +10.5% | 1.6% |
| LTM Mar 2026 | $6.65M | +20.4% | +31.0% | 2.1% | |
| LTM Sep 2026 | $2.35M | +1.4% | +61.5% | — | |
| LTM Jun 2026 | $2.14M | -66.6% | — | 1.8% | |
| LTM Mar 2026 | $1.98M | -3.3% | +34.1% | 9.2% | |
| LTM Jun 2026 | $666K | -163.6% | +106.0% | 0.4% | |
| Peer median (excluding GRDN) | $15.21M | +2.2% | +15.9% | 3.1% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 28.33M | 49.66M | 37.72M | (71.03M) | 49.22M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3.07M |
| Stock-Based Compensation | 13.03M | (3.38M) | (6.09M) | 131.49M | 13.85M |
| Change in Working Capital | (1.47M) | (18.72M) | 15.6M | (29.41M) | 6.38M |
| Accounts Receivables | (7.71M) | (16.79M) | (14.3M) | (25.49M) | (8.55M) |
| Inventory | (240K) | (8.12M) | 4.43M | (1.15M) | (877K) |
| Accounts Payables | 9.78M | 13.37M | 6.3M | 13.23M | 16.4M |
| Other Working Capital | (3.3M) | (7.17M) | 19.18M | (16M) | (586K) |
| Other Non-Cash Items | 2.08M | 4.4M | 5.35M | 7.14M | 5.43M |
| Operating Cash Flow | 58.5M | 48.52M | 70.82M | 57.96M | 100.29M |
| Capital Expenditures | (9.28M) | (16.77M) | (14.56M) | (16.37M) | (19.58M) |
| Acquisitions (Net) | (4.4M) | (2M) | (985K) | (14.71M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 535K | 874K | 2.1M | 671K | (12.68M) |
| Investing Cash Flow | (13.15M) | (17.9M) | (13.44M) | (30.41M) | (32.26M) |
| Debt Repayment | (6.1M) | (2.8M) | (2.89M) | (36.48M) | (4.98M) |
| Common Stock Issued | 0 | 0 | 0 | 119.78M | 27.45M |
| Common Stock Repurchased | 0 | 0 | 0 | (55.18M) | (29.04M) |
| Dividends Paid | (17.36M) | (30.8M) | (38.42M) | (35.75M) | 0 |
| Other Financing Activities | (13.34M) | (11.42M) | (15.92M) | (16.02M) | (497K) |
| Financing Cash Flow | (36.79M) | (45.03M) | (57.23M) | (23.65M) | (7.07M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.56M | (14.41M) | 145K | 3.91M | 60.96M |
| Free Cash Flow | 49.22M | 31.75M | 56.26M | 41.59M | 80.71M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.